News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

600 New Generic Drugs To Spur Mylan Inc. (MYL)'s Growth



6/2/2014 7:33:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Mylan Inc. is predicting strong growth over the next several years as demand for lower-cost generic medications accelerates around the world. John Sheehan, chief financial officer of the Cecil-based maker of generic and specialty drugs, told analysts and institutional investors Thursday that Mylan will reach adjusted profit of $6 a share by 2018, which would be more than double its per-share adjusted earnings of $2.89 last year. “Our growth has been massive, and it will continue over the next five years,” Sheehan said at the Invest Pennsylvania Equity Conference in the David L. Lawrence Convention Center, Downtown.

Help employers find you! Check out all the jobs and post your resume.

Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES